Synonym
GSK137647A; GSK-137647A; GSK 137647A; GSK137647; GSK-137647; GSK 137647.
IUPAC/Chemical Name
4-methoxy-N-(2,4,6-trimethylphenyl)-benzenesulfonamide
InChi Key
FQUAFMNPXPXOJE-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H19NO3S/c1-11-9-12(2)16(13(3)10-11)17-21(18,19)15-7-5-14(20-4)6-8-15/h5-10,17H,1-4H3
SMILES Code
O=S(C1=CC=C(OC)C=C1)(NC2=C(C)C=C(C)C=C2C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively.
In vitro activity:
TUG891 or GSK137647A treatment significantly decreased LPS-induced expression of il1β, il6, il8, tnfα and cox2 (P < 0.05) (Figure 2). TUG891 or GSK137647A significantly upregulated the mRNA expression of pparγ relative to the LPS treatment (P < 0.001) (Figure 2).
Reference: Front Immunol. 2021 Jun 10;12:703914. https://pubmed.ncbi.nlm.nih.gov/34177969/
In vivo activity:
The i.p. administration of FFAR4 agonist GSK137647 (1 mg/kg bw, twice daily) reversed mouse colonic injury induced by DSS, as shown in Figure 4A–C. Moreover, this study observed that during DSS-induced colitis, expression of FFAR1 was significantly increased, while FFAR2 decreased in the colon (Figure 4D).
Reference: Nutrients. 2021 Aug 6;13(8):2716. https://pubmed.ncbi.nlm.nih.gov/34444876/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
30.0 |
98.23 |
| DMSO |
55.4 |
181.36 |
| DMSO:PBS (pH 7.2) (1:2) |
0.3 |
0.82 |
| Ethanol |
8.8 |
28.67 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
305.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Wu M, Li Q, Mai K, Ai Q. Regulation of Free Fatty Acid Receptor 4 on Inflammatory Gene Induced by LPS in Large Yellow Croaker (Larimichthys crocea). Front Immunol. 2021 Jun 10;12:703914. doi: 10.3389/fimmu.2021.703914. PMID: 34177969; PMCID: PMC8222784.
2. Xu F, Zhou H, Liu X, Zhang X, Wang Z, Hou T, Wang J, Qu L, Zhang P, Piao H, Liang X. Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products. RSC Adv. 2019 May 15;9(26):15073-15083. doi: 10.1039/c9ra02142f. PMID: 35516320; PMCID: PMC9064241.
3. Salaga M, Bartoszek A, Binienda A, Krajewska JB, Fabisiak A, Mosińska P, Dziedziczak K, Niewinna K, Talar M, Tarasiuk A, Kordek R, Fichna J. Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice. Nutrients. 2021 Aug 6;13(8):2716. doi: 10.3390/nu13082716. PMID: 34444876; PMCID: PMC8399282.
In vitro protocol:
1. Wu M, Li Q, Mai K, Ai Q. Regulation of Free Fatty Acid Receptor 4 on Inflammatory Gene Induced by LPS in Large Yellow Croaker (Larimichthys crocea). Front Immunol. 2021 Jun 10;12:703914. doi: 10.3389/fimmu.2021.703914. PMID: 34177969; PMCID: PMC8222784.
2. Xu F, Zhou H, Liu X, Zhang X, Wang Z, Hou T, Wang J, Qu L, Zhang P, Piao H, Liang X. Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products. RSC Adv. 2019 May 15;9(26):15073-15083. doi: 10.1039/c9ra02142f. PMID: 35516320; PMCID: PMC9064241.
In vivo protocol:
1. Salaga M, Bartoszek A, Binienda A, Krajewska JB, Fabisiak A, Mosińska P, Dziedziczak K, Niewinna K, Talar M, Tarasiuk A, Kordek R, Fichna J. Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice. Nutrients. 2021 Aug 6;13(8):2716. doi: 10.3390/nu13082716. PMID: 34444876; PMCID: PMC8399282.
1: Sparks SM, Chen G, Collins JL, Danger D, Dock ST, Jayawickreme C, Jenkinson S,
Laudeman C, Leesnitzer MA, Liang X, Maloney P, McCoy DC, Moncol D, Rash V, Rimele
T, Vulimiri P, Way JM, Ross S. Identification of diarylsulfonamides as agonists
of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett. 2014 Jul
15;24(14):3100-3. doi: 10.1016/j.bmcl.2014.05.012. Epub 2014 May 16. PubMed PMID:
24881566.
